Strategy to targeting the immune resistance and novel therapy in colorectal cancer

Assessing the CRC subtypes that can predict the outcome of colorectal cancer (CRC) in patients with immunogenicity seems to be a promising strategy to develop new drugs that target the antitumoral immune response. In particular, the disinhibition of the antitumoral T‐cell response by immune checkpoint blockade has shown remarkable therapeutic promise for patients with mismatch repair (MMR) deficient CRC. In this review, the authors provide the update of the molecular features and immunogenicity of CRC, discuss the role of possible predictive biomarkers, illustrate the modern immunotherapeutic approaches, and introduce the most relevant ongoing preclinical study and clinical trials such as the use of the combination therapy with immunotherapy. Furthermore, this work is further to understand the complex interactions between the immune surveillance and develop resistance in tumor cells. As expected, if the promise of these developments is fulfilled, it could develop the effective therapeutic strategies and novel combinations to overcome immune resistance and enhance effector responses, which guide clinicians toward a more “personalized” treatment for advanced CRC patients.

• Publication year

  2018

• Venue

  Cancer Medicine

• Publication date

  2018-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.1386PMID 29658188PMCID 5943429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status

  2018cited by this paper
• Strategy to targeting the immune resistance and novel therapy in colorectal cancer

  2018cited by this paper
• PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?

  2018cited by this paper
• Colorectal cancer subtypes: Translation to routine clinical pathology.

  2017cited by this paper
• From tumour heterogeneity to advances in precision treatment of colorectal cancer

  2017cited by this paper
• Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer

  2017cited by this paper
• Commitment of Scaffold Proteins in the Onco-Biology of Human Colorectal Cancer and Liver Metastases after Oxaliplatin-Based Chemotherapy

  2017cited by this paper
• Colorectal tumors are enriched with regulatory plasmablasts with capacity in suppressing T cell inflammation

  2017cited by this paper
• Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients

  2017cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2017cited by this paper
• Recent developments in the treatment of metastatic colorectal cancer

  2017cited by this paper
• Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer.

  2017cited by this paper
• Curcumin up regulates T helper 1 cells in patients with colon cancer.

  2017cited by this paper
• Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.

  2017cited by this paper
• Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases

  2017cited by this paper
• Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer

  2017cited by this paper
• [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].

  2017cited by this paper
• Immunotherapy for colorectal cancer: where are we heading?

  2017cited by this paper
• Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer

  2017cited by this paper
• Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.

  2017cited by this paper
• Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer

  2017cited by this paper
• Mass Spectrometry-Based Analysis for the Discovery and Validation of Potential Colorectal Cancer Stool Biomarkers.

  2017cited by this paper
• Friend or foe? The tumour microenvironment dilemma in colorectal cancer.

  2017cited by this paper
• The potential role of platelets in the consensus molecular subtypes of colorectal cancer

  2017cited by this paper
• Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

  2017cited by this paper
• Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

  2017cited by this paper
• The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab

  2017cited by this paper
• Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.

  2017cited by this paper
• Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.

  2017cited by this paper
• Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

  2017cited by this paper
• Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer

  2017cited by this paper
• Learning in PD : Future Aspirations

  2017cited by this paper
• Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• Learning from PD-1 Resistance: New Combination Strategies.

  2016cited by this paper
• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

  2016cited by this paper
• Toll‐Like Receptors and Tissue Remodeling: The Pro/Cons Recent Findings

  2016cited by this paper
• Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice.

  2016cited by this paper
• The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression.

  2016cited by this paper
• The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.

  2016cited by this paper
• Epigenetic biomarkers in colorectal cancer: premises and prospects

  2016cited by this paper
• Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer

  2016cited by this paper
• Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Advances in targeted and immunobased therapies for colorectal cancer in the genomic era

  2016cited by this paper
• Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer

  2016cited by this paper
• [Molecular Classification of Colorectal Cancers and Clinical Application].

  2016cited by this paper
• Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine.

  2016cited by this paper
• Deciphering biological characteristics of tumorigenic subpopulations in human colorectal cancer reveals cellular plasticity

  2016cited by this paper
• Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer

  2016cited by this paper
• Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway

  2016cited by this paper
• Could B7-H4 serve as a target to activate anti-cancer immunity?

  2016cited by this paper
• Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

  2016cited by this paper
• Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

  2016cited by this paper
• Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

  2016cited by this paper
• Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II

  2016cited by this paper
• Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer

  2016cited by this paper
• Immune checkpoint therapy for non-small-cell lung cancer: an update.

  2016cited by this paper
• The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

  2016cited by this paper
• Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

  2016cited by this paper
• Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

  2016cited by this paper
• Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.

  2016cited by this paper
• Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

  2016cited by this paper
• [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].

  2016cited by this paper
• Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

  2016cited by this paper
• Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

  2016cited by this paper
• Abstract B174: FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers

  2016cited by this paper
• Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

  2016cited by this paper
• Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.

  2016cited by this paper
• Expression and localization of the immunophilin FKBP51 in colorectal carcinomas and primary metastases, and alterations following oxaliplatin-based chemotherapy

  2016cited by this paper
• Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

  2016cited by this paper
• Checkpoint inhibition for colorectal cancer: progress and possibilities.

  2016cited by this paper
• Reducing prostaglandin E2 production to raise cancer immunogenicity

  2016cited by this paper
• Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

  2016cited by this paper
• Immunotherapy of Colorectal Cancer

  2016cited by this paper
• Dendritic cell-based cancer immunotherapy for colorectal cancer.

  2016cited by this paper
• Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation.

  2016cited by this paper
• Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines

  2016cited by this paper
• The emerging role of immunotherapy in colorectal cancer.

  2016cited by this paper
• Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth

  2016cited by this paper
• Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer

  2015cited by this paper
• Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

  2015cited by this paper
• Molecular phenotypes of colorectal cancer and potential clinical applications

  2015cited by this paper
• Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Immunomodelling Characteristics of Mature Dendritic Cells Stimulated by Colon Cancer Cells Lysates.

  2015cited by this paper
• Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer

  2015cited by this paper
• Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells

  2015cited by this paper
• OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer

  2015cited by this paper
• Effector lymphocyte-induced lymph node-like vasculature enables naïve T-cell entry into tumors and enhanced anti-tumor immunity

  2015cited by this paper
• Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration

  2015cited by this paper
• CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function

  2015cited by this paper
• Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies

  2015cited by this paper
• Mutational profiling of colorectal cancers with microsatellite instability

  2015cited by this paper
• Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality

  2015cited by this paper
• Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation

  2015cited by this paper

• Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

  2026cites this paper
• Effect of colorectal cancer stem cells on the development and metastasis of colorectal cancer

  2024cites this paper
• Colonic Tuft Cells: The Less-Recognized Therapeutic Targets in Inflammatory Bowel Disease and Colorectal Cancer

  2024cites this paper
• A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

  2024cites this paper
• Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer

  2023cites this paper
• Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota

  2023cites this paper
• Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer

  2023cites this paper
• Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment

  2022cites this paper
• Classification of colorectal cancer into clinically relevant subtypes based on genes and mesenchymal cells

  2022cites this paper
• Immune Tolerance vs. Immune Resistance: The Interaction Between Host and Pathogens in Infectious Diseases

  2022influential citation
• Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children with Germline DNA Replication Repair Deficiency

  2021cites this paper
• A prognostic model for colorectal cancer based on CEA and a 48-multiplex serum biomarker panel

  2021cites this paper
• MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling

  2021cites this paper
• The Anti-Tumor Effect and Mechanism of Triterpenoids in Rhus chinensis Mill. on Reversing Effector CD8+ T-cells Dysfunction by Targeting Glycolysis Pathways in Colorectal Cancer

  2021cites this paper
• Tackling Tumour Cell Heterogeneity at the Super-Resolution Level in Human Colorectal Cancer Tissue

  2021cites this paper
• Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice

  2020cites this paper
• MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer

  2020cites this paper
• PD‐1/PD‐L1‐dependent immune response in colorectal cancer

  2020influential citation
• Glucosinolate-rich hydrolyzed extract from Moringa oleifera leaves decreased the production of TNF-α and IL-1β cytokines and induced ROS and apoptosis in human colon cancer cells

  2020cites this paper
• Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis

  2020cites this paper
• An update on colorectal cancer microenvironment, epigenetic and immunotherapy.

  2020cites this paper
• Molecular Pathogenesis and Classification of Colorectal Carcinoma

  2020cites this paper
• Epigenetic‐based therapy for colorectal cancer: Prospect and involved mechanisms

  2019cites this paper
• The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers

  2019cites this paper
• Strategy to targeting the immune resistance and novel therapy in colorectal cancer

  2018cites this paper
• Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status

  2018cites this paper
• PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?

  2018cites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper